Celltex Therapeutics initiates Wellness Protocol Clinical Trial in Mexico

Celltex Therapeutics Corporation asserted its authorization to conduct an investigational protocol which is a Phase II B Wellness Protocol Clinical Study on Rheumatoid Arthritis and Osteoarthritis (No. 173300ES450822/2017) by the Comisión Federal Para La Protección Contra Riesgos Sanitarios Comisión de Autorización Sanitaria (COFEPRIS), which is Mexico’s equivalent governmental regulatory body to the US FDA.

Celltex will extend adult autologous adipose tissue-derived  mesenchymal stem cells cultured and cultivated by Celltex’s stem cell process that renders adult autologous AdMSCs in quantities not possible for for use in therapies for vascular, autoimmune, and degenerative diseases as well as injuries.

The trial set to take place at Hospital Galena which is a  a private hospital awarded with three international accreditations: Consejo De Salubridad General (Mexico), Joint Commision International, and Accreditation Canada International. The modern facility presents an advanced medical infrastructure with highly-trained physicians in the field of regenerative medicine, responsible for the application of the stem cell therapy under the Wellness Protocol Clinical Study.

Celltex Chief Executive Officer David Eller stated “This trial is an important stride in continuing the advancement of the possibilities of AdMSCs for regenerative medicine breakthroughs in Mexico and in the United States.”